Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 76Breast 5Gynecologic 4Thoracic 3Genitourinary 3Sarcoma 2Head & Neck 2Dermatologic 2CNS 2Plasma cell 1Myeloid 1Lymphoid 1

Conditions

Squamous Cell Carcinoma of Head and Neck 280Head and Neck Neoplasms 257Nasopharyngeal Carcinoma 127Oropharyngeal Neoplasms 57Carcinoma, Squamous Cell 54Nasopharyngeal Neoplasms 41Laryngeal Neoplasms 35Mouth Neoplasms 30Hypopharyngeal Neoplasms 29Carcinoma 24Salivary Gland Neoplasms 19Carcinoma, Non-Small-Cell Lung 16Tongue Neoplasms 15Neoplasm Metastasis 13Laryngeal Diseases 13Recurrence 12Neoplasms 10Parkinson Disease 4, Autosomal Dominant Lewy Body 8Mucositis 8Stomach Neoplasms 7Pharyngeal Neoplasms 7Papillomavirus Infections 7Ovarian Neoplasms 7Lung Neoplasms 7Radiation Injuries 6Pancreatic Neoplasms 6Neoplasms, Squamous Cell 6Esophageal Neoplasms 6Colorectal Neoplasms 6Thyroid Neoplasms 5

Interventions

pembrolizumab 9Nivolumab 4Magnetic Resonance Spectroscopy 3spartalizumab 2Ipilimumab 2Gemcitabine 2Fluorodeoxyglucose F18 2FAPI-46 2Drug Therapy 2Cisplatin 2zenocutuzumab 1venetoclax 1ulixertinib 1trametinib 1tislelizumab 1seribantumab 1rovalpituzumab tesirine 1pazopanib 1neratinib 1margetuximab 1lenvatinib 1entrectinib 1durvalumab 1cobimetinib 1cemiplimab 1budigalimab 1bemarituzumab 1atezolizumab 1alectinib 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Cisplatin × Head & Neck × Clear all
NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Eli Lilly and Company

Phase 1 Active not recruiting
200 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡